ASA1-OT15

**ASA1-OT15** is an experimental **peptide-drug conjugate** described in preclinical medicinal chemistry research for **glioblastoma**. It consists of the salicylanilide-derived small molecule **ASA1** conjugated through an oxime linkage to an **oligotuftsin carrier peptide** used for glioblastoma-targeting delivery; in the source series, oligotuftsins are described as ligands of **neuropilin receptors** intended to enhance tumor-cell internalization and tissue penetration. In U87 glioblastoma cells, ASA1-OT15 and related conjugates reduced cell viability, and salicylanilide-induced cell death was associated with **autophagy activation**. The compound appears to be a **research-stage academic construct** rather than a clinically developed therapeutic candidate, and no commercial developer, manufacturer, brand name, dosage form, route, or clinical development program was identified from the provided evidence.